-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $30

Benzinga·07/13/2026 13:01:05
语音播报
BMO Capital analyst Evan David Seigerman maintains Pfizer (NYSE:PFE) with a Outperform and lowers the price target from $34 to $30.